ClinConnect ClinConnect Logo
Search / Trial NCT06603064

Neuromodulation of Brain and Emotional Responses to Psychological Stress

Launched by UNIVERSITY OF PITTSBURGH · Sep 16, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Stress Emotion Transcranial Magnetic Stimulation Tms Functional Magnetic Resonance Imaging F Mri Neuromodulation Cardiovascular

ClinConnect Summary

This clinical trial is studying how a non-invasive technique called transcranial magnetic stimulation (TMS) can affect how people respond emotionally to stress. The researchers want to see if gently stimulating the brain can help healthy adults manage anxiety better during stressful situations. Participants will take part in tasks while undergoing MRI scans, which are special imaging tests that show brain activity. They will have two visits: one where they receive the actual brain stimulation and another where they receive a placebo, which feels similar but doesn’t provide any real stimulation.

To be eligible for this study, participants need to be between 30 and 50 years old, speak English at home for the past ten years, and live in the Pittsburgh area for at least six weeks. There are some health conditions and medications that could exclude someone from participating, so it’s important to review those carefully. During the study, participants can expect to complete tasks while their brain activity is monitored through the MRI, allowing researchers to see how brain stimulation might influence their emotional responses to stress. It's a unique opportunity to contribute to research that could help understand anxiety better!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 30 to 50
  • 2. English language proficiency (English as the primary language used in the home for the past 10 years)
  • 3. Report that they will reside in the Pittsburgh area for at least 6 weeks, to maintain scheduling availability
  • Exclusion Criteria:
  • 1. Medication Use
  • 1. The following medications can affect brain and cardiovascular measures being obtained in this study; thus, use of the following medications on one or more occasions in the past 14 days constitutes grounds for exclusion:
  • Antihypertensive or cardiac medications (diuretics, beta blockers, calcium channel blockers, ACE inhibitor/ARB, cardiac glycosides, central sympatholytic HTN drugs, anti-arrhythmic drugs, vasodilator drugs, other cardiac drugs)
  • Anticonvulsant medications
  • Anti-Parkinson medications
  • Protease inhibitors or other Anti-HIV medications
  • Medications for the treatment of mania, including antipsychotics
  • All other centrally active or psychotropic medications, excluding anxiolytic and antidepressant medications.
  • Insulin
  • Chemotherapy
  • Immunosuppressants and related biological agents (Imuran, methotrexate, and cyclophosphamide)
  • Prescription weight loss medications and ephedrine OTC
  • 2. Reported use of the following medications on a "regular" basis is grounds for exclusion. For this purpose, "regular use" is defined as reporting that the prescribed medication was taken 7 or more days in the past 14 days. Individuals who take these medications, but less frequently than 7 out of the past 14 days are not excluded:
  • Short-lasting benzodiazepines
  • Asthma oral medications
  • Asthma/allergy inhalants
  • Antidepressant medications
  • Glucocorticoids (e.g., oral prednisone, cortisol)
  • Medical marijuana
  • 3. The following medications can affect the CNS for 24 hours following administration; thus, reported use of the following medications within 48 hours of scanning is excluded:
  • Longer acting benzodiazepines
  • Sleep medications (e.g., trazodone)
  • 4. Reported use of more than 2 non-insulin medications for diabetes on a "regular" basis is grounds for exclusion. For this purpose, reported use of combination medications, involving two or more non-insulin medications for diabetes in a single pill, is counted as 2 separate medications and would be grounds for exclusion.
  • 5. A person who reports that he or she was once on a disallowed medication but has discontinued this medication for at least a month or longer and is otherwise eligible, is allowed to participate in the study.
  • 2. Substance use exclusions:
  • 1. Anyone reporting 35 or more alcoholic drinks in the last 7 days is excluded.
  • 2. Anyone reporting consumption of 6 or more alcoholic drinks on 3 or more occasions in the past 7 days is excluded.
  • 3. Anyone reporting use of illicit drugs on 7 or more days in the past 2 weeks is excluded.
  • 3. Medical conditions:
  • 1. Epilepsy or a history of seizures.
  • 2. Self-reported prior heart attack, stroke, bypass surgery, angioplasty, congestive heart failure, arrhythmia (cardiac rhythm problems).
  • 3. Severe hypertension (SBP/DBP \> 160/and/or \>100 mmHg)
  • 4. Cancer (treatment in last 12 months, allowances for non-melanoma skin cancer)
  • 5. Liver disease
  • 6. Kidney disease
  • 7. Type I diabetes
  • 8. Self-reported history of a major neurological disorder or brain injury resulting in ongoing symptoms or cognitive impairment (e.g., multiple sclerosis, cerebral palsy, major head injury)
  • 9. Self-reported chronic psychotic illness (schizophrenia, bipolar disorder)
  • 10. Lung disease requiring drug treatment (note however that asthma or allergy inhalers are not exclusionary unless they are used on a "regular basis")
  • 4. Pregnant participants, or participants actively planning to become pregnant in the next 3 months, are excluded.
  • 5. Those with a visual impairment that would prevent them from reading printed text or text on a computer screen, iPad, or other electronic device are excluded.
  • 6. Those with color blindness, who may not be able to distinguish colors on some of the tasks used in this study, are excluded.
  • 7. Those who report that they are not comfortable with undergoing MRI because of the confined space would be excluded. If individuals are interested in the study, but unsure about their comfortability with undergoing an MRI, then they would be given the option to try going into a mock MRI, which is a replica of an MRI scanner. This is meant to aid interested individuals in determining whether they are comfortable with having an MRI. If they report that they are comfortable after this experience, then they would be eligible to continue. If not, then they would be discontinued from further participation.
  • 8. Those who use certain medical devices, implants, or other metal objects in or on the body that cannot be removed and are incompatible with use of fMRI (for example, tattooed eyeliner) are excluded. Many devices can be deemed MRI compatible with the make and model of medical device. If a participant reports a metal medical device, a letter from a medical professional with the make and model number of the device may be used to assess compatibility.
  • 9. Those who are unable to fit into an MRI scanner (over 7ft2in tall or greater than 350lbs weight) are excluded.
  • 10. Those who report working the night shift on a frequent basis (half or more of the hours worked in a full workday are between midnight and 8 am, and this has occurred more than 12 times during the past year) are excluded.

About University Of Pittsburgh

The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.

Locations

Pittsburgh, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Thomas E Kraynak, PhD

Principal Investigator

University of Pittsburgh

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported